Tagged with M

Czech Republic Adriana Stara, general manager Central Europe & Baltics at Allergan, explains how her previous experiences have prepared her to drive Allergan’s business in the region. Stara also delves into Allergan’s marketing strategy in medical aesthetics, the company’s strongest franchise locally, and the characteristics of the Czech market when it comes…

Czech Republic Bernard Bauer, CEO and board member at the German-Czech Chamber of Industry and Commerce, discusses the factors that make the German-Czech collaboration such a natural and powerful one, out of which the two countries’ common industrial tradition plays a key role. Furthermore, Bauer assesses the evolution of bilateral trade relations,…

Hungary In 2016, Hungary transitioned from a second-tier member to a full member of the EU. As Judit Bidló, deputy director general of pricing and reimbursement for Hungary’s National Institute of Health Insurance Fund Management (NEAK), explains, this has already had a significant impact on patient access to innovative new products.…

Hungary Katinka Zinnemers, managing director of Abacus Medicine, highlights the company’s mission to increase access to medicines for all patients and its commitment to building trust with authorities as it enters into the arena of parallel imports.     As a parallel trade company, we must be compliant in the same manner…

CEE Ingrid Šmerdová, General Manager of Adamed in the Czech Republic and Slovakia, shares her thoughts about the role their future product pipeline will have in continuing to build the company’s growth within the Czech generics market. Moreover, Šmerdová portrays Adamed’s family-oriented approach as a key differentiator within the pharmaceutical industry…

Hungary MD Pál Szamosújvari, Judit Jávor, Pál Szamosújvari Jr—Founder, R&D Director, and Director of Pharma Patent respectively—share their insights on the activities of the company, the importance of R&D, the challenges of smaller companies, its marketing strategy of its niche products, and its internationalization strategy.   Can you introduce yourself and…

Czech Republic Ewopharma’s Jan Krejčí, Country Manager for the Czech affiliate for the last eight years, shares the achievements of the company in its two main business pillars, prescription drugs, and consumer healthcare, and the successful entry into the hospital segment through the challenging and rewarding journey launching Santhera’s orphan drug for…

Czech Republic Miha Kline has been with Eli Lilly for the past 15 years, becoming Country Manager Czech Republic and Slovakia four years ago. Kline shares his milestones with the affiliate successfully entering new therapeutic areas and reaching 1bn CZK in sales. Kline also discusses the challenging market access conditions and the…

China Dr Yuguang Wang, CEO of Maxinovel Pharmaceuticals, recaps his three decades of industry experience across Big Pharma, biotech and CRO organizations in China and the US, his motivation to establish Maxinovel Pharmaceuticals as a global, semi-virtual biotech, and their mission to develop a pipeline of orally-active one-pill combination of immuno-oncology…

UAE Vishnu Kalra, Janssen’s managing director for the GCC region, reflects on his 18-year career with Johnson & Johnson, including his perspective on the success factors behind the company’s strong growth in the region. Moreover, he highlights Janssen’s diversified portfolio across different therapeutic areas, with neuroscience, oncology, haematology, pulmonary arterial hypertension…

USA In 2019 big pharma companies prioritised shareholder payouts and dividends, with the eight biggest US pharma companies topping $31 billion in stock buybacks and the same amount in dividends. Revenues were not necessarily consistent with dividend and buyback amounts, and some critics argue that payouts should be lessened in favour…

China 2019 was a bumper year for biotech companies listing on the Hong Kong Exchange (HKEx), with nine pre-revenue biotechs and eight revenue-generating biotech and biotech-related firms, mostly originating from mainland China, listing last year. The average amount of funds raised by these was a whopping four to five times higher…